Identification of complications in paediatric cerebral palsy treated with intrathecal baclofen pump: a descriptive analysis of 15 years at one institution

A. Imerci
K. J. Rogers
C. Pargas
J. P. Sees
F. Miller

Abstract

Purpose Intrathecal baclofen (ITB) treatment is used with increasing frequency in the cerebral palsy population. We describe the complications of ITB treatment, the incidence of complications, and our experience with their treatment.

Methods In a period of 15 years, 341 paediatric patients with cerebral palsy treated with ITB were evaluated. Device problems associated with the catheter or pump, or infection and complications such as cerebrospinal fluid (CSF) leak and postdural spinal headache, were reviewed. Infection was classified as early (≤ 90 days) or late (> 90 days) according to the time of onset.

Results The infection rate was 6.9% per procedure (50/720) and 14.6% per patient (50/341) over a mean 6.3 ± 3.9 years. There was a positive correlation between the risk of infection and preoperative comorbidities including epilepsy/seizure history, feeding tube, and mixed type cerebral palsy (p < 0.05, p = 0.03, p = 0.01, respectively). Eighty-five (24.9%) patients experienced 90 CSF leak episodes; 61 of these 85 patients had headache complaints as a result of CSF leak. There was a positive correlation between the risk of early infection and CSF leak (p < 0.05).

Conclusions The most common complication related to ITB was associated with pump and catheter problems. The rate of complications with the use of ITB is relatively high; however, based on the literature reports, it is the most effective treatment for severe spasticity and dystonia in patients with severe cerebral palsy.

Level of Evidence: III

Introduction

The intrathecal baclofen pump was developed in the 1990s, and efficacy was confirmed in children with cerebral palsy (CP) by Albright et al.1–3 Because baclofen has low lipid solubility, it has a limited ability to cross the blood–brain barrier. When giving baclofen orally, very high doses are required for severe spasticity, and, even with high doses, tolerance develops.3 In cases of persistent spasticity not alleviated by oral therapy or other conservative treatment modalities, baclofen may be administered intrathecally.4 Penn and Kroin5 reported that after intrathecal administration to treat severe spasticity, muscle tone was immediately reduced. With intrathecal administration, the problem of poor absorption across the blood–brain barrier was overcome, and very low baclofen doses were able to achieve a much higher cerebrospinal fluid (CSF) concentration. Intrathecal baclofen (ITB) treatment has been found to be safe and effective in severe spasticity, and its use has also been documented to be effective in children with CP.6–10

Although ITB is an effective treatment option, there are complications associated with the surgical technique and long-term treatment requiring an implanted mechanical device. The complications include side effects associated with baclofen (such as overdose and withdrawal), CSF leakage, postdural spinal headache, infection, wound dehiscence and seroma, which may be seen in the early postoperative period, and mechanical problems such as pump and catheter problems that may occur in the late period.11–15 The next step in ITB pumps is to improve results in children with CP, decrease complication rates, and increase quality of life with these complications.

The aim of this study was to describe the rates of complications after treatment of 341 paediatric patients with CP treated consecutively with ITB to evaluate risk factors over a 15-year period.
Methods

This study was a retrospective chart review begun after approval by our hospital’s institutional review board. Paediatric patients with CP treated with ITB between 2004 and 2018 were included. Implantation was performed by experienced paediatric orthopaedists. The adjustment and refilling of the test dose were carried out by the physiatrist. Complications were managed by the paediatric orthopaedist.

A separate intrathecal injection as a trial to evaluate the outcome was recommended prior to implants.\(^{16}\) We realized early on that for spastic quadriplegia Gross Motor Function Classification System (GMFCS) IV and V, very little clinical information is gained from these trials whilst incurring risk of a CSF leak; therefore, we only carried out trials for a small number of ambulatory children. The catheter insertion site varied between the L1 and L5 intrathecal space. After obtaining good backflow, the CSF pressure was measured with a manometer. The catheter tip was adjusted according to the clinical situation using fluoroscopic control. If the aim was primarily for lower extremity spasticity reduction, the catheter tip was placed at mid to lower thoracic levels (T6–T10). If the goal was to reduce upper extremity spasticity or dystonia, the catheter tip was placed at C5–T1 levels. A SynchroMed II pump (SynchroMed, Medtronic Inc., Minneapolis, MN) was implanted subcutaneously and anchored to the abdominal fascia or between the external and internal oblique muscles. The trial was a separate procedure in which the effectiveness of baclofen was evaluated by injecting baclofen as a single dose into the intrathecal space prior to placement of an ITB catheter. This review includes several catheter and pump versions, and we have not made any separation for the specific model of either the catheter or the pump.

Gross Motor Function Classification System level, type of spasticity, seizure history, feeding-tube status, and inpatient events were recorded from review of the medical record. Intrathecal baclofen trials, primary ITB applications, and posterior spinal fusion (PSF) interventions were recorded during ITB treatment period. Complications such as CSF leaks, headache, mechanical problems related to pump or catheter, infections, drug associated with side effects, pump malfunction, wound dehiscence, and seroma were recorded. Because of these complications, catheter or pump replacement or revisions, catheter removal procedures, treatment methods, and dates were recorded. Pump replacement due to an expiring battery was not considered a complication.

Infection was classified as early (≤ 90 days) or late (> 90 days) according to the time of onset.\(^{17}\) Cerebrospinal fluid leak was recorded as posterior when it was under the lumbar incision or posterior wound, anterior if it was around the pump or anterior wound, and on either side if it caused swelling on both sides. To make the differential diagnosis between CSF leak swelling or infection abscess, we routinely aspirated under sterile conditions in cases where infection vs. CSF leak was unclear. Often, it was immediately clear that there was completely clear fluid indicting a likely CSF leak or grossly purulent material indicating infection; however, samples were always sent for gram staining and culture. Usually CSF leaks were seen in the first two weeks after a dural puncture; however, some may occur later because of catheter fracture or disconnection. Cerebrospinal fluid leak was often accompanied by a complaint of spinal headache. The device problems included overdose or withdrawal of ITB; catheter fracture, kinking, occlusion, slippage, or pullout; and the pump failed, flipped, or became disconnected from the catheter. The occurrence of headache within five days after the ITB interventions, orthostatic pain, and agitation after sitting for 15 minutes or standing up to 15 minutes were symptoms used for the diagnosis of spinal headache.\(^{18}\) At the same time, spinal headache was considered when there was no other reason especially if a CSF leak was also present.

Statistical analysis

This study was a retrospective cohort study. Parametric and non-parametric analyses were performed. Descriptive and frequencies statistics were used to describe the population by mean and standard deviation. Chi-squared tests were used to compare GMFCS, complication type, spinal headache, CSF leak, infection, and reoperation status. Statistical analysis was performed using SPSS v25 (IBM, Armonk, NY, USA). Significance was set at p < 0.05.

Results

This review includes 341 patients with CP who were treated with ITB during a 15-year period (2004–2018). These 341 patients had 64 pre-implantation baclofen trials. Mean follow-up time was 6.3 ± 3.9 years (range six months to 15 years). The number of males (205) was higher than females (136). Demographic characteristics of the patients are presented in Table 1. The mean implantation age was 12.0 ± 4.4 years. Before primary ITB implantation, an intrathecal trial dose was performed in 64 of 341 (18.7%) patients. The C7–T1 level was where the catheter tip was most frequently placed (254 patients, 74%).

A total of 720 ITB procedures were recorded (Table 2). Overall, the mean complication rate was 0.44 per implant. The mean time between primary ITB and secondary ITB because of the complications was 3.8 ± 2.1 years. The mean time between primary ITB and replacement because of the end of the battery life was 5.2 ± 3.8
years. The mean time between replacement and second replacement in these patients was 4.7 ± 2.7 years. The PSF was accompanied by primary ITB pump implantation in 31 patients, and 94 patients had pump or catheter replacement or both during PSF not related to any malfunction.

Infection

The infection rate was 6.9% per procedure (50/720) and 14.6% (50/341) in the whole patient population over a mean 6.3 ± 3.9 years (range 0.5 to 15 years). These infections were treated with antibiotic administration and a total of 67 with operative irrigation and debridement. Eighteen (36%) patients required a pump removal and secondary ITB re-implantation for the infection. It was seen that seven (2%) of the late infections followed primary ITB and 13 (3.4%) followed secondary ITB procedures. Early and late infection risks did not increase after planned procedures because of the end of the battery life (respectively, p = 0.492 and p = 0.239), but secondary procedures because of the pump and catheter problems increased the risk of early and late infection (respectively, p = 0.034 and p = 0.013). Similarly, 19 patients had early infection and eight patients had CSF leak complaints, and there was a positive correlation between the risk of early infection and CSF leak (p < 0.05). There was a positive correlation between the risk of infection and preoperative comorbidities including epilepsy/seizure history, feeding tube, mixed-type CP, and dystonic type CP (p < 0.05, p = 0.01, p < 0.05, p < 0.05, respectively). Gross Motor Function Classification System III and V increased the incidence of CSF leakage (p = 0.02 and p = 0.04).

Forty-one complaints of CSF leak or headache or both spontaneously resolved. Twenty-three patients with CSF leak and headache, one patient with only CSF leak, and two patients with only headache did not respond to conservative procedures, and a total of 33 epidural blood patches (EBP) were applied. The CSF leak was treated with a secondary ITB procedure in 20 patients (23.5%); two patients had cranioplasty cement used to close the spinal fusion laminectomy site and two patients had dura mater repair. An ITB revision was performed in a patient with CSF leak because of a pseudomeningocele. After CSF leakage, two patients had seroma formation in the pump pocket, and an abdominal wound exploration was performed.

Pump- and catheter-related complications

Catheter or pump problems or both were treated with secondary ITB procedures in 75/341 (21.9% of total patient population). Distribution of device problems associated with the catheter or pump and drug-related complications are presented in Table 3 and 4. Pumps migrated intraperitoneally, or perforated through the skin, and four patients developed wound dehiscence after PSF and ITB procedures. These wounds were treated with spinal wound exploration and vacuum-assisted closure.
Table 3  Complications of intrathecal baclofen (ITB) treatment including secondary ITB procedures and number of patients.

| Complications                        | Number of ITB procedures | Number of complications | Number of patients |
|--------------------------------------|--------------------------|-------------------------|-------------------|
| Withdrawal                           | 0                        | 0                       | 10                |
| Overdose                             | 0                        | 2                       | 2                 |
| CSF leakage and/or headache          | 20                       | 185                     | 107               |
| Pump and catheter problems           | 75                       | 67                      | 67                |
| Wound dehiscence and/or seroma       | 3                        | 6                       | 6                 |
| Infection early (< 90 days)          | 8                        | 30                      | 30                |
| Infection late (> 90 days)           | 10                       | 20                      | 20                |
| Total                                | 132                      | 320                     | 150               |

Note. CSF, cerebrospinal fluid.

Table 4  Distribution of device problems associated with the catheter or pump.

| Pump and catheter problems                        | Number of events |
|--------------------------------------------------|------------------|
| Catheter hub fracture                            | 9                |
| Catheter disconnection                           | 16               |
| Catheter kinking                                 | 11               |
| Catheter occlusion                               | 19               |
| Catheter slippage                                | 3                |
| Catheter pullout                                 | 3                |
| Pump failure                                     | 2                |
| Pump flipping                                    | 4                |
| Total                                            | 67               |

Discussion

This review focused on defining the complications encountered during the treatment of children with CP with ITB. In the literature, overall complication rates vary between 4% and 30%.14,19,20 These ratios may vary depending on the type of complication, characteristics of patients, type of disease, age, and duration of follow up.11,19,21 Stetkarova et al22 reported that the overall complication rate was 56% of patients receiving an ITB pump implant. In the current study, this rate was 44% of ITB pump implants. Although Motta and Antonello14 reported the most frequent complication as a pump problem, in our study, as Dickey et al23 reported, the most frequent problem requiring a second operation was the pump’s end of battery life (44.8%), followed by pump and catheter problems and CSF leak. In the current study, 150 patients (43.9%) had at least one complication or side effect. The problems encountered with pumps and catheters required unplanned secondary surgery, and these surgeries caused other complications such as a CSF leak or headache, or both, and infections. We believe that these high rates are a reflection of our long-term follow-up period and the inclusion of all complications, not only those requiring a surgical procedure. It should also be noted that we have not evaluated different pump or catheter models.

The most frequent second procedure was the end of the battery life in 127 patients (37.2%) with a mean six years’ follow up. Twenty-six (20.4%) had battery depletion for the second ITB replacement. All were easily treated with 153 replacement procedures. In another study, the rate of replacement required because of battery depletion was 33%, and the secondary replacement rate was 6.3%.14

Infection

In our study, the total infection rate was 14.6% (50/341) over a 6.3-year follow up with a mean of 2.3 procedures per patient. To treat the infections, we had a 5.5% (19/341) secondary ITB procedure rate and 67 irrigation events. Motta and Antonello14 reported an infection rate in children of 9.3% and another series reported 9%. Ghosh et al13 reported a 21.8% rate. The infection rate we reported in a previous study was 9.5%.24 In the literature, it is generally misleading to compare the rates of infection because the incidence of infection is calculated per patient, not procedure.13,14,23,25

Vender et al19 noticed a 9.7% rate of infection per ITB procedure. Gooch et al12 found that the rate of patients requiring secondary procedures was 3.4%. Gerszten et al26 reported this rate as 4.2%. Although the infection rate was 14.6% in our study, the infection rate per ITB procedure was 4.7%. Based on a previous study, we found that this rate was 2.4% for early infection and 2.7% for late infection and infection risk was the same for subcutaneous or subfascial pump implants.24

In the literature, the rate of infection after pump replacement was found to be higher than that of the primary application.14,23,27 We found that secondary ITB procedures due to pump system problems increased the risk of infection, which is consistent with the literature. Vender et al19 stated that CSF leak was a risk factor for infection. In the study, there was a positive relationship between CSF leak and early infection.28 Similarly, 19 patients had early infection and eight patients had CSF complaints, and there was a positive correlation between the risk of early infection and CSF leak in our study. We believe that early CSF leak diagnosis and treatment might reduce the risk of secondary infection and need for multiple secondary ITB procedures leading to further complications. Infections are more likely to be associated with the frequent medical comorbidities present in GMFCS V. Seizures and feeding tubes were more common in these patients, increasing the incidence of infection.
Cerebrospinal fluid leakage and postdural spinal headache

Each ITB implantation creates a wound hematoma and a risk of CSF leak, which may cause a spinal headache. After the needle forms a dural defect, CSF leaks into the epidural space resulting in a decrease in CSF pressure and volume. This reduction is responsible for the formation of spinal headache. Therefore, patients with CSF leak developed a headache 71.7% of the amount or pattern of CSF leakage after lumbar puncture. To reduce the risk of CSF leak, we keep all patients supine for 48 hours. We found a significant correlation between the risk of CSF leakage and the history of epilepsy/seizure, preoperative comorbidities such as feeding tube, mixed type CP, and dystonic type CP. We believe that abnormal and uncontrolled movement components of dystonia may make sealing of the dural puncture at the catheter entry site slower or less stable thereby causing an increased risk of CSF leakage. In 85 (24.9%) of our cases, 90 CSF leak episodes were documented which is higher than previously published rates.14,28 A study by Taira et al29 reported the ratio of patients with CSF leak was 3.3% and another study gave a CSF leak rate of 3.9%.28 Vender and colleagues9 declared that the rate of CSF leak and pseudomeningocele requiring reoperation in children with ITB was 12%. We attributed the high rate found in our study to the inclusion of not only those who were treated but also patients with spontaneous resolution. A study by Motta and Antonello30 reported that the incidence of CSF leakage was 13.7%, 35.5% of which needed at least one blood patch, and only three chronic CSF leakages required the system to be changed while the others cleared spontaneously. Similarly, in our study, 36% of patients with CSF leak required at least one EBP, but 20 (23.5%) patients required a secondary treatment. Four patients required surgical repair. In two patients with CSF leak, there was a seroma formation in the pump pocket and abdominal exploration was performed.

Neumann et al30 found a headache incidence of 23% after intrathecal system insertion in the paediatric population; 79% received conservative treatment, and the others were completely resolved with EBP. The incidence of headache was 24.3% in our series, with 23 patients with CSF leak and headache; one patient with only CSF leak and two patients with only headache underwent EBP treatment.

Pump- and catheter-related complications

In our series, there were 75 (21.9%) patients with pump problems requiring a secondary ITB procedure. Gerszten et al26 reported that incidence of catheter-related complication was 8.3%, and Taira et al29 reported that it was 8.5%. In another study, 23% revision for malfunction secondary to the catheter problem has been reported.36 Motta and Antonello34 found that this ratio was 15.1%. Campbell et al31 found a 17.6% rate of problems associated with the catheter. Ghosh et al33 found that the rate of mechanical complications requiring revision was 19.3% during a mean 38 months’ follow up.

Programming error or device problems can cause overdose or withdrawal.32,33 In our study, 12 patients had symptoms or signs of withdrawal and overdose. Only three patients were followed up by monitoring in the intensive care unit. The problems of the other patients were not life threatening and were quickly solved with early diagnosis and making dose adjustments and bolus applications. Ghosh et al33 reported severely adverse effects associated with overdose in only one patient. Side effects in the literature are reported in case reports and are very rare complications.34,35

In conclusion, the most common complications related to ITB are associated with pump and catheter problems. The rate of complications with the use of ITB is relatively high; however, based on the literature reports, it is the most effective treatment for severe spasticity and dystonia in patients with severe CP. On the basis of our current findings over a 15-year treatment period, a patient will need approximately 3.5 procedures with a total risk of infection of 14.6% and a 19.7% risk of pump and catheter problems. Most patients with CP should be strictly followed up because of complicated medical and surgical history. The surgeon who applies ITB treatment must know how to deal with multiple complications.

Received 19 July 2019; accepted after revision 11 September 2019.

COMPLIANCE WITH ETHICAL STANDARDS

FUNDING STATEMENT
No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article.

OA LICENCE TEXT
This article is distributed under the terms of the Creative Commons Attribution-Non Commercial 4.0 International (CC BY-NC 4.0) licence (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed.

ETHICAL STATEMENT
Ethical approval: This article does not contain any studies with human participants or animals performed by any of the authors. This study was a retrospective chart review that received approval from Alfred I DuPont Children’s hospital’s institutional review board.

Informed consent: Informed consent was not required.

ICMJE CONFLICT OF INTEREST STATEMENT
None of the authors have any conflict of interest to declare.
REFERENCES

1. Albright AL, Barry MJ, Painter MJ, Shultz B. Infusion of intrathecal baclofen for generalized dystonia in cerebral palsy. J Neurosurg 1998;88:73–76.

2. Albright AL, Barron WB, Fasick MP, Polinko P, Janosky J. Continuous intrathecal baclofen infusion for spasticity of cerebral origin. JAMA 1993;270:2475–2477.

3. Miller F. Cerebral palsy. New York, NY: Springer, 2005.

4. Brennan PM, Whittle IR. Intrathecal baclofen therapy for neurological disorders: a sound knowledge base but many challenges remain. Br J Neurosurg 2008;22:508–519.

5. Penn RD, Kroin JS. Intrathecal baclofen alleviates spinal cord spasticity. Lancet 1984;1:1078.

6. Gilmartin R, Bruce D, Storrs BB, et al. Intrathecal baclofen for management of spastic cerebral palsy: multicenter trial. J Child Neurol 2000;15:71–77.

7. Pruszczynski B, Sees J, Hulbert R, et al. Continuous intrathecal baclofen infusion for spasticity of cerebral origin. JAMA 1993;270:2475–2477.

8. Miller F. Cerebral palsy. New York, NY: Springer, 2005.

9. Bonouvié LA, Becher JG, Vles JSH, Vermeulen RJ, Buizer AI; IDYS Study Group. The effect of intrathecal baclofen in dyskinetic cerebral palsy: the IDYS trial. Ann Neurol 2019;86:79–90.

10. Buizer AI, Martens BHM, Grandbois van Ravenhorst C, Schoonmade LJ, Becher JG, Vermeulen RJ. Effect of continuous intrathecal baclofen therapy in children: a systematic review. Dev Med Child Neurol 2019;61:128–134.

11. Haranahalli N, Anand D, Wisoff JH, et al. Intrathecal baclofen therapy: complication avoidance and management. Childs Nerv Syst 2011;27:421–427.

12. Gooch JL, Oberg WA, Grams B, Ward LA, Walker ML. Complications of intrathecal baclofen pumps in children. Pediatr Neurosurg 2003;39:1–6.

13. Ghosh D, Mainali G, Khera J, Luciano M. Complications of intrathecal baclofen pumps in children: experience from a tertiary care center. Pediatr Neurosurg 2013;49:138–144.

14. Motta F, Antonello CE. Analysis of complications in 430 consecutive pediatric patients treated with intrathecal baclofen therapy: 14-year experience. J Neurosurg Pediatr 2014;13:301–306.

15. Borowski A, Littleton AG, Borkhuu B, et al. Complications of intrathecal baclofen pump therapy in pediatric patients. J Pediatr Orthop 2010;30:76–81.

16. Albright AL, Barron WB, Fasick MP, Polinko P, Janosky J. Continuous intrathecal baclofen infusion for spasticity of cerebral origin. JAMA 1993;270:2475–2477.

17. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care–associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008;36:309–322.

18. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004;24 Suppl 1:3–160.

19. Vender JR, Hester S, Waller JL, Rekito A, Lee MR. Identification and management of intrathecal baclofen pump complications: a comparison of pediatric and adult patients. J Neurosurg 2006;104:9–15.

20. Kolaski K, Logan LR. A review of the complications of intrathecal baclofen in patients with cerebral palsy. NeuroRehabilitation 2007;22:383–395.

21. Lam SK, Mayer RR, Vedantam A, A Staggers K, Harris DA, Pan IW. Readmission and complications within 30 days after intrathecal baclofen pump placement. Dev Med Child Neurol 2018;60:1038–1044.

22. Stetkarova I, Yablon SA, Kofer M, Stokic DS. Procedure- and device-related complications of intrathecal baclofen administration for management of adult muscle hypertonia: a review. Neurorehabil Neural Repair 2010;24:609–619.

23. Dickey MP, Rice M, Kinnett DG, et al. Infectious complications of intrathecal baclofen pump devices in a pediatric population. Pediatr Infect Dis J 2013;32:715–722.

24. Bayhan IA, Sees JP, Nishnianidze T, Rogers KJ, Miller F. Infection as a complication of intrathecal baclofen treatment in children with cerebral palsy. J Pediatr Orthop 2016;36:305–309.

25. Fjelstad AB, Hommelstad J, Sorteberg A. Infections related to intrathecal baclofen therapy in children: adults: frequency and risk factors. J Neurosurg Pediatr 2009;4:487–493.

26. Gerszen PC, Albright AL, Johnstone GF. Intrathecal baclofen infusion and subsequent orthopedic surgery in patients with spastic cerebral palsy. J Neurosurg Pediatr 1998;88:1009–1013.

27. Albright AL, Turner M, Pattissapu LV. Best-practice surgical techniques for intrathecal baclofen therapy. J Neurosurg Pediatr 2006;10:233–239.

28. Spader HS, Boll RJ, Bowers CA, Riva-Cambrin J. Risk factors for baclofen pump infection in children: a multivariate analysis. J Neurosurg Pediatr 2016;17:756–762.

29. Taira T, Ueta T, Katayama Y, et al. Rate of complications among the recipients of intrathecal baclofen pump in Japan: a multicenter study. NeuroModulation 2013;16:266–272.
30. Neuman SA, Eldrige JS, Qu W, Freeman ED, Hoelzer BC. Post dural puncture headache following intrathecal drug delivery system placement. Pain Physician 2013;16:101–107.

31. Campbell WM, Ferrel A, McLaughlin JF, et al. Long-term safety and efficacy of continuous intrathecal baclofen. Dev Med Child Neurol 2002;44:660–665.

32. Shirley KW, Kothare S, Piatt JH Jr, Adirim TA. Intrathecal baclofen overdose and withdrawal. Pediatr Emerg Care 2006;22:258–261.

33. Walter M, Altermatt S, Furrer C, Meyer-Heim A. Intrathecal baclofen therapy in children with severe spasticity: outcome and complications. Dev Neurorehabil 2014;17:368–374.

34. Alden TD, Lytle RA, Park TS, Noetzel MJ, Ojemann JG. Intrathecal baclofen withdrawal: a case report and review of the literature. Childs Nerv Syst 2002;18:522–525.

35. Douglas AF, Weiner HL, Schwartz DR. Prolonged intrathecal baclofen withdrawal syndrome: case report and discussion of current therapeutic management. J Neurosurg 2005;102:1133–1136.